Cipla USA Recalls Cancer Drug Batches Over Manufacturing Issue
The recall involves Nilotinib capsules in two strengths—150 mg and 200 mg—distributed in the US market. The affected batches include a total of 435 cartons, comprising 271 cartons from one lot and 164 from another.
Cancer Drug | 09/03/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy